NARB upholds that 'clinically proven' claims must be substantiated regardless of supplement status
An advertising self-regulatory panel ruled that "clinically proven" supplement claims need strong evidence, and that being a dietary supplement doesn't lower the bar — a precedent that reaches GLP-1 "support" products [1].
The National Advertising Review Board (NARB), the appeals body of BBB National Programs, has upheld a National Advertising Division (NAD) decision telling Niagen Bioscience to stop using "clinically proven" claims for its Tru Niagen supplement, along with certain immune, brain and heart health claims [1]. The decision was reported on May 22, 2026 [1].
The case turned on a question that matters well beyond one NAD+ supplement: does calling something a dietary supplement change how much proof an advertiser needs before saying a product is "clinically proven"? The NARB panel said no. It concluded that NAD "applied the proper legal standard" and followed Federal Trade Commission precedent, and that the criteria for advertising claims are separate from FDA oversight of structure/function claims [1].
What the panel decided
Niagen argued that the claims at issue were structure/function claims permitted under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which the FDA administers [1]. NAD disagreed, pointing to FTC guidance that "the Commission regards DSHEA status as a regulatory (FDA) matter, not as a consideration relevant to an assessment of whether a health claim is misleading or properly supported" [1]. In short, NAD said substantiation depends on the message consumers actually take away, not on where a claim sits in the regulatory framework [1].
Carlos Lopez, senior vice president and general counsel at Niagen, said the company is "deeply disappointed by the NARB panel's decision, which we believe applies an overly restrictive standard that is inconsistent with long-standing dietary supplement law, scientific practice and established advertising precedent" [1]. Niagen also argued NAD critiqued individual studies in isolation rather than weighing the totality of the evidence, and that the ruling creates "an unworkable standard moving forward" [1]. The company said it had avoided words like "improves" or "promotes" in its language [1].
The challenger was Reus Research, a competitor, which argued the Tru Niagen claims were broad and that NAD applied standards consistent with existing NAD and FTC precedent [1]. Reus also said Niagen markets to older consumers who may be especially vulnerable to unsubstantiated claims [1]. Niagen called the challenge "clearly retaliatory," noting it had previously challenged Reus over claims for its Cata-Kor supplements — a case in which NAD found some claims supported and recommended others be modified or discontinued [1].
Roman Miroedov, Ph.D., product development lead at Cata-Kor, said the challenge was brought because "'clinically proven' is a specific claim that requires specific substantiation, and the bar for that in dietary supplements is high regardless of how a claim is classified internally" [1]. He added that the decision "confirms that the message conveyed to consumers is what matters, not the advertiser's regulatory framing" [1].
Asa Waldstein, founder and principal at Apex Compliance, said a reasonable consumer hearing "clinically proven" could think the finished product — "or at least a very comparable product form, dose, strength and use pattern" — has been studied and shown to deliver the stated result [1]. For that kind of claim, he said, "a double-blind, placebo-controlled human trial is often the gold standard" [1]. Companies can still discuss ingredient research, he said, but "if the evidence is narrower than the claim, the claim usually needs to be narrowed too" [1].
Why it matters for patients
Many consumers considering or taking GLP-1 medicines such as semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) also encounter supplements marketed as "GLP-1 support," muscle preservation or appetite products. Those products are advertised under the same rules this decision addresses.
The practical takeaway is about how to read labels and ads. Under this ruling, the phrase "clinically proven" on a supplement is not a regulatory safe harbor and does not automatically mean the finished product at that dose was tested in humans [1]. NAD and NARB looked at what a reasonable consumer would understand the ad to say, and required the evidence to match that message [1]. Calling a statement a structure/function claim does not lower the evidence required in advertising [1].
It is important to note what this case is not. Niagen emphasized that the dispute concerns interpretation of advertising claims, not the safety or quality of its products [1]. NAD and NARB are self-regulatory bodies run through BBB National Programs; the sources do not describe any fine, recall or FDA action here [1].
What happens next
The article reports that NARB upheld NAD's recommendations and the panel thanked both Niagen and Reus "for participating in industry self-regulation in the interest of promoting truth in advertising" [1]. Whether Niagen will change specific ad language, and by when, is not stated in the source. Nor is it known from the source whether the FTC will take any separate action.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.